Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. GLP-1 agonist drugs like Ozempic and Wegovy have surged in popularity during the last ...
A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
GlobalData on MSN1d
GLP-1RAs and opioid use disorder: a new frontier in addiction treatmentGlucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
Swiss drugmaker Roche began a study last year of its experimental drug, RG6237, as a monotherapy in people with high body ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback